The treatment of primary biliary cirrhosis is directed at relief of symptoms. Complications of the disease are the result of prolonged cholestasis: pruritus, jaundice, hypercholesterolemia with xanthoma, and xanthomatous neuropathy, fat malabsorption, and osteopenia. Therapy is not effective for the hypercholesterolemia, and the pruritus, which responds early to the bile salt-sequestering resin, cholestyramine, may with time become refractory to such therapy. Based on prior reports of the efficacy of plasmapheresis in hypercholesterolemia,' 2 xanthomatous neuropathy,2 and pruritus,3 4 we undertook a study of plasma exchange in five patients with primary biliary cirrhosis to answer the following questions: (1) can plasmapheresis effect sustained lowering of serum cholesterol levels with improvement of xanthomas and painful xanthomatous neuropathy? (2) Cholesterol (mmol/l) 14-7 9 22-9 7.4 11-3 4-5 15-7 9-1 25-3 pruritus, resorption of xanthomata, and elimination of the pain caused by xanthomatous neuropathy, accompanied by a reduction in serum cholesterol. Additionally, the symptoms of Sjogren's syndrome and Raynaud's phenomenon appear to be reduced. The mechanism of these effects is removal from the body of cholesterol and bile salts (or other pruritogens) which are normally excreted via the bile. Relief of the Sjogren's or Raynaud's symptoms may depend upon removal of other substances -for example, immune complexes, but this is not clear. The effect of plasmapheresis on liver function and on the long term prognosis of primary biliary cirrhosis cannot be assessed from this study. If immune aberrations are aetiologic as suggested by Sherlock'" and others,'2 long term apheresis, by removing autoantibodies or immune complexes, could possibly alter the basic disease mechanism; this remains to be shown. What does seem clear is that chronic plasmapheresis has a role in improving the quality of life for patients with primary biliary cirrhosis with intractable pruritus and/or the complications of protracted hypercholesterolemia. The rate of progression of the disease seems to be slowed as life expectancy is otherwise very short in patients with primary biliary cirrhosis and extreme rises in bilirubin.13
Over a three year period encompassing 317 procedures, we have found plasmapheresis to be a safe therapeutic modality. Mild urticaria and transient hypotension have occurred several times but always with rapid response to fluids, albumin, and adrenaline. In contrast, Rubenstein14 recently reported three cases of anaphylaxis in 22 patients receiving therapeutic plasma exchange, manifested by urticaria, bronchospasm, and hypotension. Fatal pulmonary microvascular occlusion developed in an additional patient after an apheresis procedure. Thus, caution must be exercised, and patients closely followed after initiating plasmapheresis. biliary cirrhosis. 
Role of plasmapheresis in primary

